Uniquely integrated formulation, device and development capabilities
We effectively integrate all technologies and disciplines required to deliver an inhaled product.
- 09 Apr 2018 | Financial reports Annual report and Accounts for the 12-months ended 31 December 2017
- 21 Mar 2018 | Presentations and webcasts Preliminary Results for the 12-months ended 31 December 2017
our strategic priorities
- Leveraging rare product and device capabilities in lower risk, high-return programmes Focus on:
- Inhaled Generics
- Vectura enhanced therapies
- Simplifying processes and procedures to drive operational efficiency and reduce costs
- Managing R&D investment in line with guidance
- Seeking to partner existing programmes that no longer meet our investment criteria
- Partnering new generic and enhanced delivery development programmes
- Leveraging strong and growing cash flows from inhaled market portfolio
- Continued commitment to capital allocation discipline
- Ensuring our culture and behaviour are supportive of our strategic objectives
Our uniquely integrated formulation, device and development capabilities allow us to deliver the most complex products.